All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-ZP025 | Human anti-MAGE-C2 T cell receptor (2), pCDTCR1 | Human | 2 | Human | ALKDVEERV | HLA-A2 | Lentiviral vector | |
TCR-ZP026 | Human anti-MAGE-C2 T cell receptor (1), pCDTCR1 | Human | 1 | Human | LLFGLALIEV | HLA-A2 | Lentiviral vector | |
TCR-ZP027 | Human anti-MAGE-C2 T cell receptor (3), pCDTCR1 | Human | 3 | Human | KVLEFLAKL | HLA-A2 | Lentiviral vector | |
TCR-ZP031 | Human anti-MAGE-C2 T cell receptor (EB81-CTL16), pCDTCR1 | Human | EB81-CTL16 | Human | ALK | HLA-A2 | Lentiviral vector | |
TCR-ZP032 | Human anti-MAGE-C2 T cell receptor (EB81-CTL40), pCDTCR1 | Human | EB81-CTL40 | Human | ALK | HLA-A2 | Lentiviral vector | |
TCR-ZP033 | Human anti-MAGE-C2 T cell receptor (EB81-CTL4), pCDTCR1 | Human | EB81-CTL4 | Human | LLF | HLA-A2 | Lentiviral vector | |
TCR-ZP034 | Human anti-MAGE-C2 T cell receptor (EB81-CTL6), pCDTCR1 | Human | EB81-CTL6 | Human | LLF | HLA-A2 | Lentiviral vector | |
TCR-ZP035 | Human anti-MAGE-C2 T cell receptor (EB81-CTL11), pCDTCR1 | Human | EB81-CTL11 | Human | LLF | HLA-A2 | Lentiviral vector | |
TCR-ZP036 | Human anti-MAGE-C2 T cell receptor (EB81-CTL41), pCDTCR1 | Human | EB81-CTL41 | Human | LLF | HLA-A2 | Lentiviral vector | |
TCR-ZP037 | Human anti-MAGE-C2 T cell receptor (EB81-CTL1), pCDTCR1 | Human | EB81-CTL1 | Human | ASSTLYLVF | B52 | Lentiviral vector | |
TCR-ZP038 | Human anti-MAGE-C2 T cell receptor (LB2586-CTLA), pCDTCR1 | Human | LB2586-CTLA | Human | SESIKKKVL | B44 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION